DNAtrix unveils positive Phase 2 DNX-2401 study results at SNO Meeting
Category: #health  By Pankaj Singh  Date: 2019-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

DNAtrix unveils positive Phase 2 DNX-2401 study results at SNO Meeting

 

  • The company’s drug candidate DNX-2401 in combination with Pembrolizumab depicted clinical benefit in brain tumors like Recurrent Glioblastoma.
     
  • Study data showed interim median overall survival duration of more than a year.

DNAtrix, Inc., a clinical stage, privately held biopharmaceutical firm that focuses on oncolytic virus immunotherapies to treat cancers, reportedly presented updated efficacy and safety results from its Phase 2 fully-enrolled CAPTIVE / KEYNOTE-192 DNX-2401 study during the 2019 SNO Meeting.

The study focused on assessing the efficacies of DNX-2401 (tasadenoturev), a oncolytic adenovirus developed by DNAtrix, followed by pembrolizumab in patients suffering from recurrent glioblastoma.

The outcomes showcased that the therapy evokes a durable clinical activity while also having a favorable safety profile. Positive study outcomes were presented at the 2019 SNO (Society for Neuro-Oncology) Annual Meeting that was held between November 22-24 in Phoenix, Arizona.

Overall, 48 patients suffering from recurrent glioblastoma were treated across 15 participating clinical facilities with the DNX-2401 regimen, followed by pembrolizumab. Following the treatment, a majority of the patients witnessed clinical benefits, including durable partial and complete responses.

The interim medial overall survival duration for patients is presently 12.3 months. Additionally, the interim safety analysis showcases that the treatment has a favorable benefit-risk profile. No unanticipated adverse events were recorded, and patients stayed on pembrolizumab for over 5.5 months with 34 cycles.

Presenting author of the Phase 2 study, Clark Chen, MD, PhD, stated that the positive data possesses great promise for individuals affected by glioblastoma, a commonly occurring adult brain cancer form. The disease is associated with uniform fatality and the outcomes are striking in that context.

Dr. Chen further added, the data suggests that the DNX-2401 and pembrolizumab combination could potentially revolutionize glioblastoma patient care. The company looks forward to conducting thorough studies that are focused at validating the overall efficacy of DNX-2401.

The CEO of DNAtrix, Frank Tufaro, PhD, stated that the interim data from the company’s CAPTIVE study is a significant milestone for DNAtrix to develop DNX-2401 as a novel, innovative glioblastoma treatment.

Source credit: https://www.dnatrix.com/view.cfm/123/2019-press-release

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
By Pankaj Singh

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company ha...

VMware plans to acquire Nyansa to expand its SW-WAN portfolio
VMware plans to acquire Nyansa to expand its SW-WAN portfolio
By Pankaj Singh

  The deal for the acquisition will close in the first quarter of the FY2021 The terms of the deal have not been disclosed by the company yet VMware, a leading provider of virtualization and cloud computing software and services, recently ...

Rogers Communications launches 5G network services across Canada
Rogers Communications launches 5G network services across Canada
By Pankaj Singh

  The network will first be implemented in Toronto, Vancouver, Montreal and Ottawa Rogers has collaborated with Ericsson to provide the required technology to develop the network Rogers Communications – a Toronto based telecommunicat...